Trials
SAN DIEGO, CA: Ongoing Dialogue With FDA Aimed at Initiating Clinical Trial for IND # 15376 ...
JERSEY CITY, NJ: JERSEY CITY, NJ -- (Marketwired) -- 09/29/14 -- Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, ...
SOUTH SAN FRANCISCO, CA: SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/22/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the Independent Data Monitoring Committee (IDMC) has completed the planned ...
FOSTER CITY, CA: FOSTER CITY, CA -- (Marketwired) -- 09/17/14 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, PhD, Chief Executive Officer, will present a corporate overview an ...
BOSTON, MA: Stockholders Approved All Proposals in the 2014 Proxy ...
BOSTON, MA: Decreasing Image Interpretation Variability in Cancer Trials Can Result in Decreased Trial Sample Size, Thus Driving a Decrease in Trial Cost ...
CARLSBAD, CA: CARLSBAD, CA -- (Marketwired) -- 11/06/13 -- International Stem Cell Corporation (OTCQB: ISCO) () a California-based biotechnology company developing novel stem cell based therapies and biomedical pr ...
JERSEY CITY, NJ: JERSEY CITY, NJ -- (Marketwired) -- 10/30/13 -- Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, ...
BOSTON, MA: BOSTON, MA -- (Marketwired) -- 10/29/13 -- WorldCare Clinical (WCC), a leading CRO focused on maximizing the precision and accuracy of independent assessments in clinical trials, today announced a ne ...
PARSIPPANY, NJ: 27% Increase in Third Quarter 2013 Net Revenue to $174.3 Million; 26% Increase YTD September 2013 Net Revenue to $502.9 Million; Net Income in Third Quarter 2013 Totals $7.8 Million or $0.12 per Share ...
BOSTON, MA: BOSTON, MA -- (Marketwired) -- 10/09/13 -- , a leading imaging CRO focused on maximizing the precision and accuracy of independent assessments in clinical trials, today announced that Melissa Gebhard ...
TUSTIN, CA: Bavituximab Pivotal Phase III Lung Cancer Trial Named "SUNRISE" on Track for Initiation by Calendar Year-End; Bavituximab Pre-Clinical Proof-Of Concept Studies Underway to Support Potential ...
TUSTIN, CA: Presentation Reviews Bavituximab's and Docetaxel's Compatible Immune-Stimulating Properties Further Supporting Initiation of Phase III Trial in Second-Line NSCLC by Year-End; Proof-of-Concep ...
PHOENIX, AZ: Reports Record Revenue of $18.8 Million and EPS of $0.26 per Diluted Share ...
BOSTON, MA: New Service Enables Combination Tumor Assessments Using Both RECIST and irRC ...
MELBOURNE, AUSTRALIA: MELBOURNE, AUSTRALIA -- (Marketwired) -- 07/03/13 -- Prana Biotechnology (NASDAQ: PRAN) (ASX: PBT) today announced that it has received approval from the Austin Health Human Research Ethics Committee ...
MONTREAL, QUEBEC: MONTREAL, QUEBEC -- (Marketwired) -- 06/05/13 -- Bioniche Life Sciences Inc. (TSX: BNC)(ASX: BNC) ("Bioniche") and Paladin Labs Inc.(TSX: PLB) ("Paladin") today announced a compr ...
